Patients with chronic myeloid leukemia who become resistant to the Abl kinase inhibitor imatinib can be treated with dasatinib. This sequential treatment can lead to BCR-ABL mutations conferring broad resistance to kinase inhibitors. To model the evolution of resistance, we exposed the mouse DA1-3b BCR-ABL þ leukemic cell line to imatinib for several months, and obtained resistant cells carrying the E255K mutation. We then exposed these cells to dasatinib, and obtained dasatinib-resistant cells with composite E255K þ T315I mutations. Subcloning isolated a minor clone also carrying V299L. In co-culture, mutated cells were able to spread resistance to non-mutated cells through overexpression of interleukin 3, activation of MEK/ERK and JAK2/STAT5 pathways, and downregulation of Bim. Even the presence of less than 10% of mutated cells was sufficient to protect non-mutated cells. Blocking JAK2 and MEK1/2 inhibited the protective effect of co-culture. Mutated cells were also sensitive to JAK2 inhibition, but blocking MEK1/2 alone, or in association with kinase inhibitors, had little effect. These data indicate that sequential Abl kinase inhibitor therapy can generate sub-populations of mutated cells, which may coexist with non-mutated cells and protect them through a paracrine mechanism. Targeting JAK2 could eliminate both populations.
Introduction
Imatinib is an Abl-specific inhibitor that efficiently inhibits the BCR-ABL tyrosine kinase. It can induce complete molecular remission in patients with chronic myeloid leukemia (CML) or with BCR-ABL þ acute lymphoblastic leukemia. However, resistance can occur after months or years of continuous treatment, by selection of subclones. Resistance involves various mechanisms, including point mutations of the BCR-ABL kinase domain. To overcome this, dasatinib, a SRC and ABL kinase inhibitor has been developed. It too binds to mutated BCR-ABL and is now routinely used in patients who become resistant to imatinib. [1] [2] [3] Dasatinib treatment can lead to new BCR-ABL mutations. Some, like T315I, confer resistance to both imatinib and dasatinib, and others, like V299L, confer resistance to dasatinib only. 2, 4, 5 Thus, the leukemic cells from a patient with resistant CML have been exposed for months to a succession of two kinase inhibitors, and it has been recently shown that this sequential treatment selects for clones with composite mutations, which confer increased oncogenic potency. 2 Besides BCR-ABL point mutations, other mechanisms of drug resistance have been identified, for example, BCR-ABL amplification and drug efflux. In the DA1-3b BCR-ABL mouse model of tumor dormancy, dormant leukemic cells that persist for 1 year, in spite of an immune response, develop resistance to apoptosis through an interleukin (IL) 3 autocrine loop. 6 This IL3 loop also led to imatinib resistance, even though these cells had never been exposed to kinase inhibitors, and did not show any BCR-ABL mutations. Thus, cells can become resistant to kinase inhibitors through BCR-ABL-independent mechanisms. These data raise the question of whether the point mutations are sufficient to induce drug resistance, or whether they act alongside other mechanisms.
To investigate this, we established an in vitro model mimicking the sequential treatment of patients. For some months, we cultured the DA1-3b BCR-ABL cell line first in imatinib, then in dasatinib. Besides occurrence of point mutations that confer resistance to both drugs, resistant cells overproduce IL3, which can spread drug resistance to nonmutated cells through MEK/ERK and JAK2/STAT5 pathways.
Materials and methods

Cell line and kinase inhibitors
The leukemic DA1-3b BCR-ABL-expressing cell line and the DA1-3b/C3H mouse model have been described previously. 7, 8 Briefly, DA1 IL3-dependent cells were electroporated with a pCDNA3 expression vector (Invitrogen, San Diego, CA, USA) carrying a p210 BCR/ABL cDNA, and transduced cells were selected by culture in IL3-free medium. Imatinib (Novartis Pharmaceuticals, East Hanover, NJ, USA) was stored at À20 1C as a 10 mM stock solution in distilled water. Dasatinib (BristolMyers Squibb, New York, NY, USA) was stored at À20 1C as a 10 mM stock solution in dimethyl sulfoxide.
Cell cycle and proliferation assay
Cell proliferation was analyzed by using the CellTiter96 Aqueous One Solution Cell proliferation assay kit (Promega, Madision, WI, USA) according to the manufacturer's protocol. Cell cycle was analyzed by flow cytometry of DNA content, and assessed with propidium iodide according to conventional techniques.
Apoptosis and signal transduction analysis
Cell viability was assessed by phosphatidyl-serine exposure, measured with a fluorescein isothiocyanate-conjugated annexin V labeling kit and propidium iodide staining according to conventional methods. Western blot analyses were performed with the following antibodies: polyclonal anti-phospho ERK1/2 (Thr202/Tyr204), anti-phospho STAT1 (Tyr701), anti-phospho STAT5 (Tyr694), anti-c-ABL, anti-p53, monoclonal anti-phospho Bad (Ser112, clone 7E11) (Cell Signalling Technology, Danvers, MA, USA); anti-Bim, anti-Bax, anti-Bcl-2, anti-Bcl-xL, anticleaved caspase-3 (Asp175), all from Sigma-Aldrich, St Louis, MO, USA; monoclonal anti-phosphotyrosine (clone 4G10; Upstate, Lake Placid, NY, USA) and anti-MCL-1 (Rockland, Philadelphia, PA, USA).
To study the signal transduction pathway involved in imatinib and dasatinib resistance, the following cytokines and reagents were used: AG490 JAK2 inhibitor (25 mM), PD98059 MEK1 inhibitor (25 mM), SB203580 p38MAPK inhibitor (3 mM), LY294002 PI-3K inhibitor (25 mM), SP600125 JNK inhibitor (25 mM; Biosource, Camarillo, CA, USA); U0126 MEK1/2 inhibitor (20 mM; Cell Signalling Technology) and recombinant human IL3 (Peprotech, Rocky Hill, NJ, USA).
Bim siRNA
Small interfering RNA (siRNA) oligonucleotides targeting endogenous mouse Bim EL, L and S (Santa Cruz, Santa Cruz, CA, USA), and a control nonspecific siRNA, were transfected into 2 Â 10 6 DA1-3b cells at 150 mM final concentration, using the Amaxa Nucleofector device (Amaxa, Kö ln, Germany) with Cell Line specific Nucleofector kit V (program U15) according to the manufacture's instructions. After electroporation, cells were transferred to 5.0 ml of complete medium and cultured for 24 h before treatment. Effects of siRNA transfection on Bim expression were confirmed by western blotting.
Co-culture and conditioned medium experiments
To analyze the protective effect of imatinib-and dasatinibresistant cells on imatinib-sensitive cells, we co-cultured resistant (mutated) cells with sensitive (unmutated) DA1-3b cells, using a six-well ThinCert culture system (Greiner Bio-one, Courtaboeuf, France), which consists of two compartments separated by a microporous PET membrane (0.4 mm diameter pore). DA1-3b/M1, M2 and M3 cells were cultured for 24 h at 1 Â 10 5 cells ml À1 in the upper compartment and DA1-3b or DA1-3b/M1 cells in the lower compartment at the same concentration. Dasatinib or imatinib were then added, and cell viability was analyzed 48 h later.
The protective effect of resistant cells was also studied using conditioned medium (CM). Resistant DA1-3b/M1-M3 cells were cultured for 24 h in 1% fetal calf serum RPMI1640 at an initial concentration of 1 Â 10 6 cells ml À1 . CM was harvested, centrifuged twice for 10 min to clear cell debris, and then added to DA1-3b cells or DA1-3b/M1 cells.
To analyze if cell-cell interaction mediated drug resistance, resistant cells (DA1-3b/M1-M3) were fixed with 2% formaldehyde for 15 min and washed two times with complete medium, then mixed with the same number of DA1-3b cells. The cell mixture was treated with 1 mM imatinib or 0.5 mM dasatinib for 48 h, and cell viability was analyzed. The number of fixed cells in each group was constant and was estimated from the final cell viability.
Cytokine dosage and blocking experiments
In CM from various cell lines, production of IL-2, -3,-4, -6,-10, -12, -15, granulocyte-colony stimulating factor (G-CSF) and granulocytemacrophage colony-stimulating factor (GM-CSF) was analyzed by conventional ELISA methods. In IL3 blocking experiments, an anti-mouse IL-3 monoclonal antibody (clone MP2-8F8, Tebu) or its control isotype rat IgG was used at 2 mg ml À1 .
Statistical analyses
Statistical analyses were performed using Sigma Stat 3.1 (SPSS Science).
Results
Establishment of imatinib-and dasatinib-resistant cell lines
The mouse DA1-3b cell line carrying a p210
BCRÀABL cDNA was first cultured in 0.05 mM imatinib for 180 days. Then imatinib concentration was progressively increased up to 3 mM (Figure 1a ). After 310 days, imatinib-resistant cells were obtained and were named DA1-3b/M1. Sequencing the BCR-ABL kinase domain revealed an E255K mutation in the p-loop. Analysis of 10 subclones obtained by limiting dilution did not show any other mutation. DA1-3b/M1 showed almost complete resistance, up to 10 mM imatinib ( Figure 1b ). But DA1-3b/M1 was highly sensitive to dasatinib, with no significant differences between it and imatinib-sensitive DA1-3b.
Next, we cultured DA1-3b/M1 in 10 nM dasatinib and progressively increased the concentration to 2 mM. After 170 days, we obtained cells that showed resistance to dasatinib up to 10 mM (Figure 1c ). We named these DA1-3b/M2. Sequencing the BCR-ABL kinase domain showed a T315I mutation. Analysis of 10 subclones obtained by limiting dilution showed nine clones with composite mutations E255K and T315I, and one clone with three mutations, E255K, T315I and V299L ( Figure 1a ). This subclone was named DA1-3b/M3 and showed the same resistance profile to imatinib and dasatinib as DA1-3b/M2 ( Figure 1c ).
To investigate if selective pressure was required to maintain the BCR-ABL mutations, we cultured DA1-3b/M1, M2 and M3 without inhibitors. After 100 days, mutations were still detected, and resistance to inhibitors remained identical, indicating that selective pressure was necessary to select mutations, but not to maintain them.
Cell proliferation assays performed without inhibitors showed no differences between cell lines. However, cell-cycle analysis showed that DA1-3b/M3 had a slightly higher proportion of cells in S phase (Supplementary Figure S1) . Injection of the resistant cell lines into syngeneic C3H/Hej mice showed no significant differences in tumorigenicity (Supplementary Figure S2) .
During the selection of resistant cells, we extracted and stored DNA after each increase in drug concentration, allowing us to determine a posteriori when the BCR-ABL mutations had occurred. E255K was detected when imatinib rose to 1 mM (100 days after starting imatinib; Supplementary Table 1A) . T315I was detected when dasatinib rose to 1 mM (151 days after starting dasatinib, 331 days after starting the sequential selection process; Supplementary Table 1B) . This suggests that BCR-ABL mutations emerge when a threshold of inhibitor concentration or culture time is crossed. However, BCR-ABL cells can become resistant to kinase inhibitors below this threshold without mutations, suggesting that other mechanisms of resistance exist.
MEK/ERK, STAT5 and Bim in resistant cell lines
MEK/ERK and STAT5 pathways are downstream effectors of the BCR-ABL kinase.
9-12 DA1-3b/M1, and to a lesser degree DA1-3b/M2, showed increased ERK phosphorylation, but STAT5 phosphorylation was identical (Figure 2a) . In DA1-3b, imatinib and dasatinib reduced phosphorylation of ERK, STAT5 and BCR-ABL (Figure 2c) . Imatinib was still able to partially reduce MEK and STAT5 phosphorylation in DA1-3b/ M1, but dasatinib was not able to do so in DA1-3b/M2 and DA1-3b/M3. The imatinib-resistant line DA1-3b/M3 carries, in addition to E255K and T315I, V299L, which has been reported in patients to be resistant to dasatinib but sensitive to imatinib.
2 ERK and STAT5 were not affected in these cells either by imatinib or dasatinib, and basal phosphorylation of ERK was slightly lower in DA1-3b/M3 (Figure 2c) . Expression of Bim, the main mediator of apoptosis induced by imatinib and dasatinib, was higher (Figure 2b) . 13 No difference of FoxO3A expression, which regulates Bim expression, could be observed. Thus, DA1-3b/M3 was just as resistant to dasatinib and imatinib as DA1-3b/M2 cells, in spite of high Bim expression.
Transmission of imatinib and dasatinib resistance from mutated to non-mutated cells through soluble factors
As BCR-ABL mutations were not detected during the first 3 months of culture, when imatinib dose was above 1 mM, we hypothesized that, during early culture, an additional mechanism protected non-mutated cells from imatinib.
We co-cultured DA1-3b with imatinib-resistant DA1-3b/M1, or with dasatinib-resistant DA1-3b/M2 and M3, using the ThinCert two-compartment communicating system. Co-culture conferred an almost complete protection from imatinib, and partial protection from dasatinib ( Figure 3a) . Next, we performed the same experiments with different ratios of DA1-3b to DA1-3b/M2. The protective effect started at 16:1 ratio, and a 4:1 ratio protected most cells (Figure 3b) . Thus, the presence of only 6.3% of imatinib-resistant cells can protect a larger population of imatinib-sensitive cells. As the cells were separated by a permeable membrane, we hypothesized that soluble factors may mediate the protective effect. Absence of protective effects in co-culture experiments performed with fixed cells was also in favor of this hypothesis (Supplementary Figure S3) .
Conditioned medium (CM) from resistant cells mediated the same resistance as co-culture (Figure 3c ). We quantified several cytokines in the CM, and found that resistant cells produced significantly higher levels of IL3, which were not affected by incubation in imatinib or dasatinib (Figure 3d ). Recombinant IL3 protected DA1-3b from imatinib and dasatinib, even at a dose as low as 10 pg ml À1 (Figure 4a ). Adding IL2, IL6 or GM-CSF had no effect (Supplementary Figure S4) , while adding anti-IL3 blocking antibody to the co-culture abolished the protective effect (Figure 4b) . Thus, IL3 overexpressed by mutated cells is able to spread resistance to sensitive cells. However, blocking IL3 had little effect on mutated cells, indicating that the paracrine effect was not associated with an autocrine effect, and that the mutation alone is sufficient to protect these cells from imatinib and dasatinib (Supplementary Figure S5) .
IL3 produced by mutated cells activates JAK2/STAT5 and MEK/ERK in non-mutated cells
In BCR-ABL-expressing cells, the JAK2, STAT5 and MEK/ERK pathways are active. 14 We investigated whether IL3 produced by mutated cells can activate these pathways in other cells, and thus rescue cells exposed to imatinib. Co-culture of DA1-3b with mutated cells increased ERK1/2 and STAT5 phosphorylation, and this was not reduced by imatinib. IL3 induced phosphorylation of STAT5 and ERK1/2 in DA1-3b (Figure 4c ). STAT5 phosphorylation was blocked by the JAK2 inhibitor AG490, and ERK1/2 phosphorylation was blocked by the MEK1/2 inhibitor UO126. Thus, when sensitive cells are exposed to imatinib and dasatinib, IL3 produced by mutated cells can activate the JAK2/STAT5 and MEK/ERK pathways and maintain hyper-phosphorylation.
Blocking JAK2/STAT5 and MEK/ERK induces apoptosis in mutated and non-mutated cells
We investigated whether blocking the pathways activated by IL3 can restore sensitivity to kinase inhibitors. When sensitive cells were co-cultured with mutated cells, or with rIL3, the JAK2 inhibitor AG490, and to a lesser degree the MEK1/2 inhibitor UO126, blocked the protective effect (Figure 5a ). Thus, targeting these pathways can prevent the spread of resistance from mutated to non-mutated cells.
We also tested MEK and JAK2 inhibitors on mutated cell lines. Targeting MEK has been reported to synergize with dasatinib and imatinib. 9, 15 In cells with mutated BCR-ABL, blocking JAK2 alone induces apoptosis.
14 In DA1-3b/M1, DA1-3b/M2 and DA1-3b/M3, UO126 had limited effect, alone, or associated with imatinib, or with dasatinib ( Figure 5b ). Targeting PI3-K with LY294002, p38MAPK with SB203580, and JNK with SP600125, was not effective. However, AG490 alone induced apoptosis in mutated cell lines with E255K alone, E255K þ T315I or E255K þ T315I þ V299L (Figures 5b and c) . Addition of imatinib 
IL3 protects non-mutated cells through downregulation of Bim
In imatinib-treated BCR-ABL cells, Bim is reportedly the main inducer of apoptosis. 13 We evaluated the role of Bim in DA1-3b. Bim siRNA inhibited Bim expression and blocked imatinibinduced apoptosis, thus confirming Bim's role (Figure 6a We also analyzed the effect of JAK2 and MEK1/2 inhibition on Bim expression in mutated cells. AG490 induced the strongest expression of Bim, confirming the efficacy of JAK2 targeting in BCR-ABL mutated cells (Figure 6d ).
Discussion
Treatment with dasatinib is now a therapeutic standard in patients who relapse or are intolerant or resistant to imatinib. Two recent publications have reported emergence of successive BCR-ABL mutations in patients treated first with imatinib, then with dasatinib, nilotinib or bosutinib.
1,2 These mutations coincided partially with those observed from in vitro mutagenesis studies. 4, [16] [17] [18] Thus, screening mutations in vitro for conferring resistance to kinase inhibitors may be able to predict resistance in vivo. However, these experiments involved short exposures to kinase inhibitors, perhaps not allowing enough time for cells to develop additional mechanisms of resistance. Patients are frequently exposed for months or years to imatinib before being switched to another inhibitor, and then exposed to that for long periods, before disease progression.
Here, we exposed the DA1-3b BCR-ABL cell line to increasing doses of imatinib over 6 months, and then to dasatinib for a further 5 months. The mutations found resemble those discovered in patients: an E255K p-loop mutation in imatinib-resistant cells, followed by a T315I mutation that blocks accessibility to kinase inhibitors in dasatinib-resistant cells. A surprising finding was the isolation of a minor clone also carrying the V299L mutation that has been observed in patients resistant to dasatinib, some of whom were sensitive to imatinib. 1, 2 This triple mutant showed different characteristics from other dasatinib-resistant clones carrying only E255K and T315I: the percentage of cells in S-phase was slightly increased and it expressed more Bim. However, all cell lines mutated or not grew identically, in vitro or in vivo.
Proliferation or survival advantage conferred by BCR-ABL mutations is still controversial. In some studies but not others, E255K and T315I increase BCR-ABL phosphorylation and target downstream proteins. [19] [20] [21] Increased or decreased clonogenicity, oncogenesis and growth in low serum conditions have also been reported. Our data indicate that in BCR-ABL cell lines the mutations principally confer resistance to a specific kinase inhibitor. However, the finding of a minor clone with an additional mutation suggests that several populations of resistant mutated cells can coexist for long periods.
We detected the E255K mutation only when cells had become resistant to 1 mM imatinib, after 3 months of culture. This suggests that other mechanisms, besides mutation participate in resistance. Resistant cells overexpressed IL3, and the cytokine spreads imatinib resistance and partial dasatinib resistance to non-mutated cells. A small population of mutated cells was able to protect a larger population of non-mutated cells. Blocking IL3 had little effect on mutated cells, indicating that the paracrine effect was not associated with an autocrine effect, and that the mutation alone is sufficient to protect these cells from imatinib and dasatinib. Autocrine growth loops with IL3, GM-CSF or G-CSF have been described in BCR-ABL cell lines and in CD34 þ cells from CML. [22] [23] [24] [25] Recently, Wang et al. 26 reported increased secretion of GM-CSF, in imatiniband nilotinib-resistant cells from the LAMA cell line, and in CD34 þ progenitors from some imatinib-resistant patients with CML. This cytokine was able to protect cells naive to imatinib or nilotinib by activating JAK2/STAT5 and MEK/ERK. However, it was not clear if GM-CSF contributed to resistance through an autocrine loop, or protected imatinib-sensitive cells through a paracrine effect. Our data suggest that the cytokine's paracrineprotective effect may lead mutated and non-mutated cells to coexist for months during exposure to kinase inhibitor before the increase in the inhibitor eliminates non-mutated cells.
IL3 protects BCR-ABL cells extremely effectively from apoptosis. Mutated cells produced fourfold more IL3 than non-mutated cells, but the absolute quantities produced were low. Thus, research on paracrine-protective loops in resistant leukemic cells should focus not only on cytokines that are abundant but also on those that have biological significance.
IL3 protects myeloid cells from apoptosis through activation of STAT5 and MEK/ERK. [27] [28] [29] [30] We observed that blocking JAK2 or MEK1/2 abolished the protective effect of co-culture on imatinib-induced apoptosis. However, only JAK2 inhibition was able to induce apoptosis in imatinib-or dasatinib-resistant cells. BCR-ABL activates JAK2, which contributes to the tumorigenicity of leukemic cells. Blocking JAK2 with AG490 induces apoptosis of BaF3 cells expressing BCR-ABL mutations T315I and E255K.
14 Our results confirm these data and indicate that JAK2 inhibition could eliminate both resistant cells and sensitive cells. Eradication of resistant cells in patients would probably suppress the paracrine-protective effect of cytokines like IL3. But sensitive cells could also be protected by cytokines coming from the microenvironment, thus allowing a small population of leukemic cells to survive and to acquire new mutations. Thus, JAK2 blocking is a tempting strategy to eliminate residual leukemic cells.
Imatinib killing of BCR-ABL cells is mediated by Bim overexpression and Bad hypo-phosphorylation. 13 Reduction of MCL1, BCL2 and BCL-xL has been observed in some studies but not in others. [31] [32] [33] [34] Our data confirm the essential role of Bim, and also indicate a possible role for MCL1, BCL-xL, Bad and Bax. We observed that apoptosis of resistant cells, induced through JAK2 blocking, was characterized by overexpression of Bim, while MEK1/2 blocking had little effect. This confirms that JAK2 is an important mediator of protection from apoptosis in BCR-ABL cells. The protective effect of IL3 on non-mutated cells was associated with the opposite profile of BCL-xL, MCL1, BAX, pBAD and Bim, to that observed after exposure to imatinib. This profile was reversed by JAK2 and MEK1/2 blocking, confirming that targeting these pathways could eliminate cells protected through the paracrine effect.
In summary, we observed that sequential treatment of BCR-ABL cells with imatinib and dasatinib results in cells carrying composite mutations; these resistant cells can protect non-mutated cells from imatinib, and to a lesser degree from dasatinib, through a paracrine mechanism. This suggests that in patients resistant to kinase inhibitors, the population of leukemic cells can be heterogeneous, but could be eliminated through JAK2 inhibition. 
